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Abstract
Background: Glucose is a more efficient substrate for ATP production than free fatty acid (FFA). Insulin resistance (IR) 
results in higher FFA concentrations and impaired myocardial glucose use, potentially worsening ischemia. We 
hypothesized that metabolic manipulation with a hyperinsulinemic euglycemic clamp (HEC) would affect a greater 
improvement in left ventricular (LV) performance during dobutamine stress echo (DSE) in subjects with IR.
Methods: 24 subjects with normal LV function and coronary disease (CAD) awaiting revascularization underwent 2 
DSEs. Prior to one DSEs they underwent an HEC, where a primed infusion of insulin (rate 43 mU/m 2/min) was co-
administered with 20% dextrose at variable rates to maintain euglycemia. At steady-state the DSE was performed and 
images of the LV were acquired with tissue Doppler at each stage for offline analysis. Segmental peak systolic velocities 
(Vs) were recorded, as well as LV ejection fraction (EF). Subjects were then divided into two groups based on their 
insulin sensitivity during the HEC.
Results: HEC changed the metabolic environment, suppressing FFAs and thereby increasing glucose use. This resulted 
in improved LV performance at peak stress, measured by EF (IS group mean difference 5.3 (95% CI 2.5-8) %, p = 0.002; IR 
group mean difference 8.7 (95% CI 5.8-11.6) %, p < 0.0001) and peak V s in ischemic segments (IS group mean 
improvement 0.7(95% CI 0.07-1.58) cm/s, p = 0.07; IR group mean improvement 1.0 (95% CI 0.54-1.5) cm/s, p < 0.0001) , 
that was greater in the subjects with IR.
Conclusions: Increased myocardial glucose use induced by HEC improves LV function under stress in subjects with 
CAD and IR. Cardiac metabolic manipulation in subjects with IR is a promising target for future therapy.
Background
Insulin increases myocardial glucose utilization and
reduces free fatty acid (FFA) oxidation via several mecha-
nisms[1-4]. Glucose oxidation is more oxygen efficient
than FFA oxidation[5], hence this change in myocardial
metabolism is theoretically beneficial to the heart[5],
especially during ischemia, and is thought to be the main
mechanism behind the beneficial effects seen in the vari-
ous trials of glucose-insulin-potassium infusions[6-8].
The presence of insulin resistance (IR) or type 2 diabe-
tes has been shown to affect the metabolic pathway of
glucose at multiple levels, from uptake into the myocyte,
through to final oxidation within the mitochondria. It has
long been known that the subjects with IR are at much
greater risk of heart failure and death when compared to
insulin sensitive (IS) subjects and these differences can-
not be accounted for by other risk factors such as hyper-
tension and vascular disease[9,10].
We hypothesized that altering the myocardial meta-
bolic environment, by creating hyperinsulinemia whilst
maintaining euglycemia, would improve ischemic left
ventricular function during dobutamine stress in subjects
with known coronary artery disease (CAD) and that this
effect would be greater in IR subjects.
Methods
Subjects
Consecutive subjects with angiographically normal left
ventricular (LV) function and symptomatic CAD, await-
ing revascularization of stenoses ≥ 75%, were invited to
participate. Recruitment was carried out over an 18
month period from a tertiary referral centre for cardiol-
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Page 2 of 10ogy. Exclusion criteria included LV ejection fraction (EF)
of < 40% (either on echocardiography or LV angiogra-
phy), type 2 diabetes mellitus receiving insulin therapy,
significant valvular heart disease, atrial fibrillation, per-
manent pacemakers or severe co-morbidities. The study
had ethical approval from the Local Research Ethics
Committee and all subjects gave written informed con-
sent before participating. The study conformed with the
principles set out in the Helsinki Declaration.
Study design
Each subject underwent two dobutamine stress echocar-
diograms (DSEs) one week apart, thereby acting as their
own controls. Both scans were performed before subjects
underwent their planned revascularization. One DSE,
determined randomly, was performed during the steady-
state phase of a hyperinsulinemic, euglycemic clamp
(HEC).
Dobutamine stress echocardiography
Subjects attended for both studies after an overnight fast
and their beta-blocker therapy was withheld for 48 hours
prior to their attendance. Any oral hypoglycemic agents
were stopped 12 hours prior to the studies. After acquir-
ing the resting images, dobutamine was infused intrave-
nously via the antecubital fossa at a starting dose of 10
mcg/kg/min and increased every 3 minutes to doses of
20, 30 and 40 mcg/kg/min. Up to 1.2 mg of atropine, in
doses of 300 mcg, was given to subjects who had not
reached target heart rate (85% of predicted maximum
heart rate) or any other end-point. Subjects underwent
continuous 12-lead ECG monitoring, with blood pressure
being recorded at baseline and at the end of each stage of
dobutamine.
Standard clinical endpoints were used, including intol-
erable symptoms (such as chest pain), > 2 mm of planar
or down-sloping ST-segment depression, persistent
arrhythmias such as ventricular tachycardia or atrial
fibrillation, and hypotension (a fall of systolic pressure 30
mmHg) or bradycardia.
Image acquisition
All echocardiographic images were obtained with a stan-
dard, 2D echocardiography system (Vivid Seven, GE
Medical Systems) and stored digitally. Standard apical
views of the LV were acquired at rest and at each stage of
dobutamine stress with the patient in the left recumbent
position. To minimize beat-to-beat variability, all record-
ings were made in gently held end-expiration and stored
for subsequent off-line analysis (Echo PAC PC software,
GE Medical Systems).
Analysis
An expert observer blinded to the clinical data and tissue
Doppler results performed all the echocardiographic
analyses. The ejection fraction (EF), left ventricular end-
diastolic volume (LVEDV) and end-systolic volume
(LVESV) were calculated from the apical views using the
modified Simpson's biplane method[11]. From these
measurements, stroke volume (SV) and cardiac output
(CO) were then also calculated.
Tissue Doppler imaging
Acquisition
Color tissue Doppler imaging (TDI) was used to assess
longitudinal myocardial tissue velocities and myocardial
strain generation at baseline and each stage of dobu-
tamine stress. The filter was set to exclude high frequency
signal, and the Nyquist limit was set to 24 cm/s to mini-
mize aliasing during stress. The sector angle and imaging
depth were minimized to maintain adequate frame rates
of at least 140 frames per second.
Analysis
Off-line analysis was performed by one observer, blinded
to the nature of the study. A 6 × 6 mm sampling area was
applied to the annulus, basal and mid segments of each
wall of the LV. Apical segments were not analyzed for
velocity because off-line velocities in these segments have
been shown to be unreliable[12]. Analysis of myocardial
strain was performed on all 16 LV segments. A 6 by 12
mm sample area was placed in the middle of each seg-
ment. It was then tracked semi-automatically throughout
each cardiac cycle to ensure that it remained in the mid-
dle of the segment and did not sample the LV blood pool.
Peak systolic (Vs) velocity and post-systolic strain (PSS)
were recorded from 3 beats and averaged for each sample
point. These measurements were chosen as they have
been shown to be the more sensitive and reproducible
TDI markers of ischemia in DSE[12-16]. The intraob-
server and interobserver variability for TDI measure-
ments in our intuition are 11% and 17% respectively.
The LV segments were classified as either 'ischemic' or
'non-ischemic' on the basis of the anatomy of the subject's
coronary artery disease and the predicted arterial blood
supply to each segment, based on the guidelines from the
ASE[17].
Hyperinsulinemic, euglycemic clamp
A hyperinsulinemic euglycemic clamp was performed as
described previously[18]. After patients had fasted over-
night, a cannula was inserted into a vein in the antecu-
bital fossa for infusion of glucose and insulin. A second
cannula was inserted in the opposite arm, which was
arterialized using a heating pad set at 50°C. After an ini-
tial loading dose, insulin (Human Actrapid, Novo Nor-
disk) was infused at a constant rate of 43 mU/min/m 2 of
body surface area. Blood glucose levels were sampled
every 5 to 10 minutes from the opposite cannula and ana-
lyzed using the glucose oxidase method (YSI 2300, YSI
Life Sciences, Ohio). Glucose infusion rates were adjusted
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levels[18]. Once steady state was achieved, as indicated
by 3 consecutive blood glucose values that were within
5% of one another, the subjects underwent DSE as
described above. The insulin infusion was stopped at the
end of the peak dobutamine stress stage, along with the
dobutamine infusion, but the glucose continued for an
additional 20 minutes to avoid rebound hypoglycemia.
Assessment of insulin resistance
The glucose clamp technique, originally developed by
DeFronzo et al.[18], is widely accepted as the reference
standard for directly determining metabolic insulin sensi-
tivity in humans[19]. After at least one hour of constant
insulin infusion, steady-state conditions can typically be
achieved for plasma insulin, blood glucose and the glu-
cose infusion rate. It is assumed that the hyperinsuline-
mic state is sufficient to completely suppress hepatic
glucose production. Accordingly, since there is no net
change in blood glucose concentrations under steady-
state clamp conditions, the glucose infusion rate must be
equal to the glucose disposal rate, and this value is termed
M-value. Thus, whole body glucose disposal at a given
level of hyperinsulinemia can be determined directly. M-
value is typically normalized to body weight or fat-free
mass to generate an estimate of insulin sensitivity (mg/
kg/min).
Biochemical analysis
In addition to blood glucose sampling, serum insulin, c-
peptide (both using commercially available AutoDELFIA
Automatic Immunoassay kits, PerkinElmer, Waltham,
MA) and FFA (modified Roche Free Fatty Acid enzymic
colorimetric kit assay) concentrations were measured at
baseline, steady state (pre-DSE), peak stress and 30 min-
utes into recovery during the clamped study and also at
baseline, peak stress and 30 minutes into recovery of the
control (unclamped) study.
The coefficients of variation for the insulin assay ranges
from 3.1% at 29 pmol/l to 1.9% at 277 pmol/l. For the c-
peptide assay: 4.8% at 472 pmol/l to 3.7% at 2056 pmol/l
and for the FFA assay: 10.6% at 112 μmol/l and 4.3% at
465 μmol/l.
Statistical analysis
The primary outcome for the study was LV EF. The study
had a 90% power to detect an absolute improvement in
EF of 5% in the clamp versus the control group with a sig-
nificance level of 0.05. The analyses were restricted to the
24 patients who had both control and clamped studies.
Descriptive summaries are expressed as the mean (stan-
dard deviations) for continuous measurements and as the
number (percentage) for categories. Comparisons
between control and clamped measurements were made
using paired Student's t-tests. Comparison between dif-
ferent stages of the clamp were done by the ANOVA
method. Fisher's exact test was used to compare the inci-
dence of PSS in the control and clamp study. The statisti-
cal software programs SPSS 12.0.1 (SPSS, Cary, NC) was
used for the statistical analyses.
Results
Twenty-six subjects were recruited of whom 24 com-
pleted the study. One subject was unable to complete the
study due to emergency admission with unstable angina,
and one subject withdrew consent. The median M-value
for the 24 subjects was 3.2 mg/kg/min. The subjects were
thus divided into two groups; those with an M-value less
than 3.2 mg/kg/min (the insulin resistant (IR) group) and
those with an M-value greater then 3.2 mg/kg/min (the
insulin sensitive (IS) group). The demographics for the
two groups are shown in Table 1. There were no differ-
ences between the two groups except for weight.
Dobutamine stress
The dose of dobutamine and atropine administered in
each group were similar. This equivalent level of pharma-
cological stress resulted in heart rates (HRs), systolic
blood pressures (SBPs) and rate pressure products (RPPs)
that did not differ significantly between the control and
clamped scans at peak dobutamine stress in either the IS
or IR group (Table 2). There were no differences between
the IS and IR groups in the hemodynamic response
shown with dobutamine stress in both control and
clamped studies.
Biochemical analyses
The metabolic responses of both groups during the clamp
are shown in Table 3 and Figure 1.
C-Peptide
The c-peptide concentrations were significantly higher in
the IR groups at every stage of the clamp.
Glucose
The baseline glucose concentration in the IS group was
lower than in the IR group (88 (14) vs. 104 (27) mg/l, p =
0.07), although this did not achieve statistical signifi-
cance. At both the steady state and peak DSE stages of the
clamp, the difference in the glucose concentration in the
IS group did achieve statistical significance.
Insulin
Baseline fasted insulin concentration in the IS group was
significantly lower than the IR group (38.9 (18.7) vs. 102
(27.6) pmol/l, p < 0.0001). Although there is considerable
overlap in insulin concentrations between normal and
insulin resistance, a fasting serum insulin concentration
of greater than the upper limit of normal for the assay
used (approximately 60 pmol/l) has been considered a
marker of insulin resistance[20,21] and this supports the
separation of the subjects into IS and IR groups using M
value. This trend in lower insulin concentration in the IS
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it did not achieve statistical significance at the peak DSE
or recovery stages.
FFA
The HEC resulted in more marked suppression of free
fatty acid production in the IS group, resulting in a signif-
icantly lower FFA concentration at steady state. This dif-
ference was negated by the profound lipolytic effect of
dobutamine at peak stress, but was again present in the
recovery stage.
2D echo measurements
The LV volumes, EF and CO are shown in Table 4. Mea-
surements were made just prior to commencing the dob-
utamine infusion ('Pre-DSE'), at peak dobutamine stress
('Peak') and 15 minutes after stopping the dobutamine
infusion ('Recovery').
Ejection fraction
The pre-DSE EF were unaffected by the clamp in both
groups. At peak stress the clamp significantly improved
the EF in both the IS group mean improvement 5.3%
(95% CI 2.5 to 8), p = 0.002; IR group mean difference
8.7% (95% CI 5.8 to 11.6), p < 0.0001), with a larger mag-
nitude effect in the IR group. At the recovery stage, the
clamp continued to have a positive effect on the IR group
(mean improvement 4.8% (95% CI, 0.7 to 8.9), p = 0.03),
but not in the IS group (mean improvement 1.4% (95%
CI, -2.1 to 5), p = 0.4).
EDV
There was no significant effect of HEC on EDV in either
IS or IR groups at any stage.
ESV
At peak dobutamine stress the ESV was significantly
reduced in the clamp study in the IR group (mean differ-
ence 5.9 (5.3) mls, p = 0.03). There was a reduction in the
ESV of the IS group at peak stress, but the magnitude of
effect was smaller than in the IR group and it did not
achieve statistical significance (mean difference 4.3 (5)
mls, p = 0.09).
Table 1: Demographics of IS and IR groups
Parameters Insulin Sensitive (IS) Insulin Resistant (IR) P
Age 64 (8) 64.2 (8) ns
Male, n (%) 11 (92) 10 (83) ns
Medication, n (%)
β-Blocker 11 (92) 11 (92) ns
Nitrate 9 (75) 6 (50) ns
Calcium Channel Blocker 2 (17) 3 (25) ns
Statin 12 (100) 11 (92) ns
Ejection Fraction, % 62.2 (4) 63.3 (6) ns
Coronary Disease, n (%)
LAD stenosis 6 (50) 10 (83) ns
LCx stenosis 4 (33) 3 (25) ns
RCA stenosis 5 (42) 5 (42) ns
Single vessel CAD 10 (83) 8 (67) ns
Two vessel CAD 1 (8) 2 (17) ns
Three vessel CAD 1 (8) 2 (17) ns
Weight (Kg) 82 (15) 97.5 (20) 0.04
BSA (m2) 1.96 (0.2) 2.1 (0.2) ns
M Value (mg/kg/min) 5.7 (1.3) 2.2 (0.7) < 0.0001
Diabetes* n (%) 3 (25) 6 (50) ns
Diet controlled 3 (25) 2 (17) ns
Metformin 0 3 (25) ns
Metformin and sulphonyl urea 0 1 (25) ns
BSA = body surface area. * = subjects with a clinical diagnosis of type 2 diabetes receiving oral hypoglycemic agents. Ns = not significant
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At the pre-DSE stage the clamp exerted no effect on
either SV or CO in either group. At peak stress both SV
and CO were significantly improved in the IR group (SV
mean difference 13.1 (8) mls, p = 0.003; CO mean differ-
ence 1.4 (0.7) l/min, p = 0.001), but not in the IS group
(SV mean difference 4.2 (7) mls, p = 0.2; CO mean differ-
ence 0.5 (1) l/min, p = 0.3). There were no significant dif-
ferences in the SV and CO in the recovery stage.
Tissue Doppler imaging
Peak dobutamine Vs
The results for the peak Vs are shown in Table 5. Paired
tissue Doppler systolic velocities (Vs) were recordable in
94.4% (272 out of 288) at peak dobutamine. The Vs veloc-
ities were consistently higher for all segments in the
clamped studies, but it was only in the IR group that this
improvement achieved statistical significance, and it was
most significant in the segments classified as ischemic (IS
ischemic segments mean improvement 0.7(95% CI 0.07-
1.58) cm/s, p = 0.07; IR ischemic segments mean
improvement 1.0 (95% CI 0.54-1.5) cm/s, p < 0.0001).
Post systolic strain (PSS)
The incidences of PSS at baseline and the development of
new PSS at peak stress and recovery are shown in Table 6.
The incidence of PSS at baseline was similar in each
group are compares well to the reported incidence of PSS
in normal myocardium[14]. At peak DSE and in recovery
in both groups the clamp resulted in fewer segments
exhibiting new PSS (i.e. segments that did not have PSS at
baseline), but this effect was most marked, and achieved
statistical significance, in the recovery stage in the IR sub-
jects (15 segments in the clamp vs. 30 in the control, p =
0.03), suggesting less post-ischemic dysfunction.
Table 2: Peak HR, blood pressure and RPP during DSE in IS and IR groups
Insulin Sensitive Insulin Resistant
Control Clamp p Control Clamp p
Max Dobutamine dose (μg/kg/min) 37.5 (4.5) 38.3 (3.9) ns 35.8 (5.1) 35 (5.2) ns
Mean Atropine dose (μg) 150 (239) 150 (239) 100 (233) 100 (233)
Hemodynamic variables
Mean %max HR achieved 83 (8) 83 (5) ns 81 (7) 80 (9) ns
Peak HR (bpm) 130 (15) 130 (10) ns 126 (10) 124 (13) ns
SBP (mmHg) 147 (21) 143 (20) ns 142 (25) 141 (25) ns
RPP (bpm.mmHg) 19026 (2850) 18554 (2925) ns 17897 (3298) 17540 (3979) ns
Ns = not significant
Table 3: Metabolic parameters for clamp studies
Glucose (mg/dl) Insulin Sensitive Insulin Resistant p C-peptide (pmol/l) Insulin Sensitive Insulin Resistant p
Baseline 88 (14) 104 (27) 0.07 Baseline 683 (291) 1251 (352) 0.001
Steady state 86 (11) 106 (13) 0.0004 Steady state 493 (219) 1124 (361) 0.0002
Peak Stress 88 (11) 106 (11) 0.0004 Peak Stress 804 (334) 1465 (524) 0.004
Recovery 93 (18) 106 (20) ns Recovery 836 (363) 1374 (646) 0.04
Insulin (pmol/l) FFA (nmol/l)
Baseline 38.9 (18.7) 102 (27.6) < 0.0001 Baseline 374 (153) 548 (299) ns
Steady state 447 (78.6) 624 (150) 0.004 Steady state 49.2 (51.3) 114 (72) 0.04
Peak Stress 386 (82.9) 523 (198) 0.06 Peak Stress 365 (160) 374 (113) ns
Recovery 90.1 (45.3) 174 (117) 0.05 Recovery 83.9 (79.1) 197 (52.1) 0.002
FFA = free fatty acids. Ns = not significant
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Figure 1 Metabolic parameters during control and clamped studies. shows the glucose, c-peptide, FFA and insulin concentrations during con-
trol, graphs (a), left, and clamped studies, graphs (b), right. The black square represents the IS group and the white circle the IR group. Numbers plotted 
are mean values and the standard errors. Detailed description of the results is in the main text. * = p < 0.05; ** = p < 0.01 for comparison between IS 
and IR group.
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This study shows that in subjects with flow-limiting CAD
alteration of myocardial substrate utilization improves LV
function during DSE in both IR and IS subjects and less-
ens post-ischemic dysfunction in IR subjects. Whilst sim-
ilar effects were seen in both groups, the magnitude was
less in the IS group and so it did not generally achieve sta-
tistical significance in this study. Overall, though, the
effects are fairly modest and whilst the sample size is
small, the improvements observed in the clamped DSE in
IR group, in particular the reduction in post-ischemic
dysfunction are likely to have clinical significance.
Left ventricular performance during stress
Euglycemic hyperglycemia during DSE significantly
improved the primary endpoint of LV EF at peak stress in
both IS and IR groups. Whilst the LV EF was significantly
improved by the HEC in the IS group, it was the only one
of the indices of LV function that was significantly
improved. Peak stress SV, ESV, CO and Vs were slightly
increased in the IS group, but not significantly so.
Whereas, in the IR group at peak stress SV, ESV, CO and
Vs were all significantly improved.
The improvements in the IR group were not limited to
the peak systolic function. Post-systolic thickening or
strain is a well reported and sensitive marker of stun-
ning[22-27]. In the IS group the clamp tended to result in
fewer segments with PSS in the recovery stage, but the
difference was not statistically significant. In the IR
group, however, the effect was far more pronounced and
statistically significant, with almost half as many seg-
Table 4: 2D echocardiographic measurements
Echocardiographic 
variables
Insulin Sensitive Insulin Resistant
Control Clamp p Control Clamp p
Pre-DSE EDV (ml) 102 (16) 99.2 (19) ns 108 (24) 103 (27) ns
ESV (ml) 38.6 (7) 36 (9) ns 40.1 (13) 37.5 (13) ns
SV (ml) 63.6 (11) 63.2 (13) ns 68 (15) 65.4 (15) ns
CO (L/min) 3.7 (0.4) 3.6 (.7) ns 4.2 (1.1) 4 (1.1) ns
EF (%) 62.2 (4) 63.8 (4.5) ns 63.3 (6) 64.3 (5.9) ns
Peak EDV (ml) 74.9 (14) 74.8 (16) ns 86.1 (22) 93.3 (28) ns
ESV (ml) 26.4 (9) 22.1 (7) 0.09 31.3 (14) 25.4 (11) 0.03
SV (ml) 48.5 (8) 52.6 (12) ns 54.8 (11) 68 (19) 0.003
CO (L/min) 6.3 (1.4) 6.8 (1.7) ns 6.9 (1.5) 8.3 (2.1) 0.001
EF (%) 65.2 (6.1) 70.4 (6.3) 0.002 64.8 (7.2) 73.5 (5.8) < 0.0001
Recovery EDV (ml) 92.2 (21) 98.7 (21) ns 103 (24) 104 (23) ns
ESV (ml) 35.5 (11) 39 (11) ns 40.5 (15) 35.8 (13) 0.09
SV (ml) 56.6 (13) 58.7 (12) ns 62 (12) 68 (12) 0.05
CO (L/min) 4.4 (0.8) 4.7 (0.8) ns 4.7 (0.8) 5 (1) ns
EF (%) 61.8 (5.9) 60.4 (4.5) ns 61.5 (7.5) 66.4 (6.7) 0.03
Ns = not significant
Table 5: Mean segmental Vs at peak dobutamine stress
Insulin Sensitive Insulin Resistant
Control Clamp n p Control Clamp n p
Annulus points 10.6 (2.5) 10.9 (2.3) 72 ns 9.0 (3.3) 10.0 (3.0) 66 0.002
Ischemic segments 8.6 (4.0) 9.3 (4.2) 57 0.07 5.9 (3.1) 6.7 (2.8) 66 < 0.0001
Non-ischemic seg. 8.4 (3.4) 8.5 (3.0) 82 ns 7.3 (3.4) 8.3 (3.6) 67 0.02
n = number of paired values used for analysis. Ns = not significant.
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compared to the control.
Metabolic environment
As expected, baseline metabolic profiles of the two
groups were different, with the IR group having higher
insulin and c-peptide concentrations. The FFA and glu-
cose concentrations were also elevated in the IR group,
but not significantly so, due in part to the sub-study being
relatively underpowered to assess these. These differ-
ences are expected, as the groups were not randomly
selected, but selected on the basis of each subject's insulin
sensitivity, measured during the HEC. Elevated fasting
glucose, insulin and FFA concentrations are all part of the
phenotype seen in insulin resistance[20,28].
At the steady state phase of the clamp, before the start
of the dobutamine stress, the differences in the metabolic
measurements persisted. Despite the higher insulin con-
centration in the IR group, lipolysis inhibition was not as
complete, with a persisting elevation of the FFA concen-
tration compared to the IS group. As one of the main
driving forces for myocardial FFA uptake and utilization
is substrate availability[29,30], it would therefore be
expected that the myocardium in the IR groups will be
using more FFAs than in the IS group and that this might
disadvantage the IR group.
Possible mechanisms
Whilst the metabolic environment just prior to com-
mencing the dobutamine stress may not have been as well
optimized in the IR group as the IS group, with presumed
higher FFA use and lower glucose use, it is apparent that
the improvement in LV performance during DSE seen
with the clamp in the IR group was greater than that
observed in the IS group. There are several possible rea-
sons to explain this, of which all or none may contribute.
The normal myocardial response to ischemia is to
increase glucose uptake, glycogenolysis and glycoly-
sis[31], as well as increase FFA oxidation[32]. Perhaps, in
insulin sensitive individuals, challenged with only modest
amounts of myocardial ischemia as in this study, this
intrinsic metabolic switch is adequate and additional
stimulation of glucose oxidation with the HEC provides
minimal incremental benefit in this group, whereas in the
IR group this intrinsic metabolic switching mechanism is
impaired but can be overcome with the HEC.
Also, insulin resistance has been shown to have several
adverse effects on the metabolism of the myocardium
that heighten the effects of ischemia. These include
reduced glucose uptake[33-35] and oxidation[36],
increased FFA uptake and oxidation[37,38] as well as
decrease in calcium transport within the sarcolemma and
alterations in myofibrillary regulatory contractile pro-
teins[39]. The net effect is a reduction in cardiac effi-
ciency[40] at rest that may predispose to diabetic
cardiomyopathy[41-43], but that also causes increases the
susceptibility of the insulin resistant heart to myocardial
ischemia and to a greater reduction in myocardial perfor-
mance for a given amount of ischemia compared with the
normal heart[44-46]. It therefore stands to reason that
insulin resistant myocardium has far more to gain by
optimization of its metabolism, so provided the hyperin-
sulinemia generated by the clamp is sufficient to over-
come the IR, then the improvement in myocardial
performance during and after ischemia will be greater
than in IS subjects.
An alternative explanation is the improved LV perfor-
mance observed in the IR group may be accounted for by
the elevated glucose and insulin concentration present
throughout the clamp stimulating greater myocardial glu-
cose uptake, compared to the IS group. However, work by
others has shown that subjects with IR can have impaired
Table 6: Number of myocardial segments with post systolic strain (PSS)
Insulin Sensitive Insulin Resistant
Baseline PSS Control Clamp p Control Clamp p
Ischemic 21 (25) 27 (32) ns 36 (31) 44 (38) ns
Non-ischemic 30 (28) 31 (29) ns 24 (32) 22 (30) ns
New PSS at Peak Stress
Ischemic 31 (48) 26 (45) ns 40 (49) 34 (47) ns
Non-ischemic 40 (52) 30 (39) ns 20 (39) 22 (42) ns
New PSS in Recovery
Ischemic 21 (33) 16 (28) ns 30 (37) 15 (21) 0.03
Non-ischemic 29 (38) 25 (33) ns 11 (22) 6 (12) ns
Data shown is n (%). Ns = not significant.
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hyperinsulinemia[47,48], making the additional hyperin-
sulinemia seen in the IR subjects in this study unlikely to
result in significantly greater myocardial glucose uptake
compared to the IS subjects, although this cannot be
proved.
Study limitations
The most significant limitation of this study is the sample
size. The study was powered to assess EF, which was
improved in both groups, and it may have been under-
powered to assess some of the other variables. It is possi-
ble, therefore, that some of the TDI variables that were
not significantly different in the IS group, but showed
trends of improvement with the clamp, failed to achieve
significance due to a lack of power.
Another limitation of this study is use of quantative
QCA to define ischemic myocardial segments as opposed
to functional imaging such as myocardial perfusion
SPECT. Subjects will have variable coronary anatomy and
functional imaging would be better as assessing which
segments were ischemic.
Also, a number of assumptions on myocardial metabo-
lism and the effect the HEC has on this have had to be
made. Direct measurement of myocardial substrate
metabolism is challenging, requiring a combination of
arterial and coronary sinus venous blood sampling or
sophisticated PET imaging with radio-labeled substrates
such as glucose and palmitate[49,50]. However, previ-
ously-reported work by others has investigated the effects
of HEC on myocardial metabolism in humans[51,52], so
the assumptions are evidence-based.
Conclusions
This study shows that hyperinsulinemic euglycemia dur-
ing DSE improves LV function in both IR and IS subjects
with flow-limiting coronary disease. It also suggests that
subjects with IR may benefit more in terms of increased
cardiac performance and reduced post-ischemic dysfunc-
tion compared insulin sensitive subjects.
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